AIM ImmunoTech

Discovery Laboratories is a biotechnology company developing its proprietary surfactant technology as surfactant replacement therapies for respiratory diseases. Surfactants are substances that are produced naturally in the lungs and are essential to the lungs' ability to absorb oxygen and to maintain proper airflow through the respiratory system. The absence or depletion of surfactants is involved in a number of respiratory diseases. The company s technology produces a precision-engineered surfactant that is designed to mimic the essential properties of natural human lung surfactant. Discovery Laboratories SRT pipeline is focused on the most significant respiratory conditions prevalent in the neonatal intensive care unit. Surfaxin is one of the company s leading products for the prevention of respiratory distress syndrome in premature infants. SRT technology is also being developed to address the various respiratory conditions affecting pediatric, young adult and adult patients in the critical care and other hospital settings. Discovery Laboratories is located in Warrington, Pa.

Merck & Co Inc in West Point is dedicated to following the science in order to address significant global health challenges. Their work focuses on improving lives by developing innovative solutions to combat health threats. Through their commitment to scientific advancement, Merck strives to make a positive impact on society and contribute to the betterment of public health worldwide. Generated from their website's infomation

UroGen Pharma Ltd is a biotech company based in Princeton, NJ, dedicated to developing and commercializing innovative solutions for urothelial and specialty cancers. Their groundbreaking therapies and clinical pipeline aim to revolutionize the treatment of these cancers by maximizing the potential benefit of local delivery through their novel RTGel technology, offering transformative, nonsurgical approaches to patients. UroGen is at the forefront of a transformative shift in urothelial and specialty cancer treatment, moving away from invasive surgeries towards nonsurgical means. Their first commercial product, JELMYTO mitomycin for pyelocalyceal solution, is the first and only FDA-approved nonsurgical treatment of its kind, utilizing their RTGel technology. With a focus on fundamentally changing the treatment paradigm, UroGen is committed to providing noninvasive therapeutic options for some of the most devastating cancers.Generated from the website